Advertisement

Molecular Neurobiology

, Volume 55, Issue 4, pp 2725–2739 | Cite as

Attenuation of Glutamate-Induced Excitotoxicity by Withanolide-A in Neuron-Like Cells: Role for PI3K/Akt/MAPK Signaling Pathway

Article

Abstract

Glutamate-induced excitotoxicity is one of the major underlying mechanisms for neurodegenerative diseases. Efforts are being made to treat such conditions with an array of natural compounds that can modulate the release of glutamate or the underlying mechanisms associated with it. Withania somnifera extract has potent pharmacologic activity similar to that of Korean Ginseng tea and is used to treat several neuronal disorders. However, to date, little efforts have been made to evaluate individual constituents of this plant for neurodegenerative disorders. Present study was carried out to investigate withanolide-A, one of the active constituents of Withania somnifera against glutamate-induced excitotoxicity in retinoic acid differentiated Neuro2a neuroblastoma cells. The results indicated that glutamate treatment for 2 h induced death in cells that was significantly attenuated by pre-treatment with MK-801 (specific NMDA receptor antagonist) and different concentrations of withanolide-A. Withanolide-A abated the glutamate-induced influx of intracellular calcium and excessive ROS production significantly. Further on, glutamate treatment resulted in increased levels of pro-apoptotic and decreased levels of anti-apoptotic proteins, and these protein levels were normalized by various doses of withanolide-A. All of these protective effects were partly due to inhibition of MAPK family proteins and activation of PI3K/Akt signaling. Thus, our results suggest that withanolide-A may serve as potential neuroprotective agent.

Keywords

Withanolide-A Withania somnifera Glutamate ROS Intracellular calcium NMDA MAPK and PI3K/Akt 

Abbreviations

NMDA

N-methyl-D-aspartate

RA

Retinoic acid

ROS

Reactive oxygen species

DMSO

Dimethyl sulfoxide

HRP

Horse reddish peroxidase

H2DCFDA

2′,7′-dichlorodihydrofluorescein diacetate

NMDARs

N-methyl-D-aspartate receptor.

DMEM

Dulbecco’s Modified Eagle Medium

Glu

Glutamate

WLA

Withanolide-A

Notes

Acknowledgements

Dr. Ahmad’s work was supported by Ramalingaswamy Fellowship of Department of Biotechnology and financial assistance (MLP6009) as well as logistic support from Council for Scientific and Industrial Research. Dr. Hamid’s research is supported by Department of Biotechnology (BT/PR/3140/PBD/17/656/2009). Additionally, research in both labs is supported by BSC-0108. Mr. Dar is thankful to University Grants Commission, India for Ph.D. research fellowship. Authors are thankful to director of the institute, Dr. Ram Vishwakarma for facilitating the work. Institutional Publication number of this manuscript is IIIM/2019/2017.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Beal MF (1992) Mechanisms of excitotoxicity in neurologic diseases. FASEB J 6(15):3338–3344Google Scholar
  2. 2.
    Olsen GM, Sonnewald U (2015) Glutamate: Where does it come from and where does it go? Neurochem Int 88:47–52CrossRefPubMedGoogle Scholar
  3. 3.
    Hu N-W, Ondrejcak T, Rowan MJ (2012) Glutamate receptors in preclinical research on Alzheimer’s disease: Update on recent advances. Pharmacol Biochem Behav 100(4):855–862CrossRefPubMedGoogle Scholar
  4. 4.
    Dar NJ, Bhat JA, Satti NK, Sharma PR, Hamid A, Ahmad M (2016) Withanone, an active constituent from Withania somnifera, affords protection against NMDA-induced excitotoxicity in neuron-like cells. Mol Neurobiol 1–13Google Scholar
  5. 5.
    Kritis AA, Stamoula EG, Paniskaki KA, Vavilis TD (2015) Researching glutamate–induced cytotoxicity in different cell lines: A comparative/collective analysis/study. Front Cell Neurosci 9:91CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Jiang Q, Gu Z, Zhang G, Jing G (2000) Diphosphorylation and involvement of extracellular signal-regulated kinases (ERK1/2) in glutamate-induced apoptotic-like death in cultured rat cortical neurons. Brain Res 857(1):71–77CrossRefPubMedGoogle Scholar
  7. 7.
    Pi R, Li W, Lee NT, Chan HH, Pu Y, Chan LN, Sucher NJ, Chang DC et al (2004) Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways. J Neurochem 91(5):1219–1230CrossRefPubMedGoogle Scholar
  8. 8.
    Molz S, Dal-Cim T, Budni J, Martín-de-Saavedra M, Egea J, Romero A, del Barrio L, Rodrigues AL et al (2011) Neuroprotective effect of guanosine against glutamate-induced cell death in rat hippocampal slices is mediated by the phosphatidylinositol-3 kinase/Akt/glycogen synthase kinase 3β pathway activation and inducible nitric oxide synthase inhibition. J Neurosci Res 89(9):1400–1408CrossRefPubMedGoogle Scholar
  9. 9.
    Shah S, Lee H, Bressan R, Yun D, Kim M (2014) Novel osmotin attenuates glutamate-induced synaptic dysfunction and neurodegeneration via the JNK/PI3K/Akt pathway in postnatal rat brain. Cell Death Dis 5(1):e1026CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Endo H, Nito C, Kamada H, Nishi T, Chan PH (2006) Activation of the Akt/GSK3β signaling pathway mediates survival of vulnerable hippocampal neurons after transient global cerebral ischemia in rats. J Cereb Blood Flow Metab 26(12):1479–1489CrossRefPubMedGoogle Scholar
  11. 11.
    Kawano T, Morioka M, Yano S, Hamada J-I, Ushio Y, Miyamoto E, Fukunaga K (2002) Decreased akt activity is associated with activation of forkhead transcription factor after transient forebrain ischemia in gerbil hippocampus. J Cereb Blood Flow Metab 22(8):926–934CrossRefPubMedGoogle Scholar
  12. 12.
    Thomas GM, Huganir RL (2004) MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 5(3):173–183CrossRefPubMedGoogle Scholar
  13. 13.
    Sweatt JD (2004) Mitogen-activated protein kinases in synaptic plasticity and memory. Curr Opin Neurobiol 14(3):311–317CrossRefPubMedGoogle Scholar
  14. 14.
    Kim EK, Choi E-J (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta (BBA) - Mol Basis Dis 1802(4):396–405CrossRefGoogle Scholar
  15. 15.
    Wiegler K, Bonny C, Coquoz D, Hirt L (2008) The JNK inhibitor XG-102 protects from ischemic damage with delayed intravenous administration also in the presence of recombinant tissue plasminogen activator. Cerebrovasc Dis 26(4):360–366CrossRefPubMedGoogle Scholar
  16. 16.
    Borsello T, Clarke PG, Hirt L, Vercelli A, Repici M, Schorderet DF, Bogousslavsky J, Bonny C (2003) A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 9(9):1180–1186CrossRefPubMedGoogle Scholar
  17. 17.
    Zhou X, Hollern D, Liao J, Andrechek E, Wang H (2013) NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors. Cell Death Dis 4(3):e560CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Dar NJ, Hamid A, Ahmad M (2015) Pharmacologic overview of Withania somnifera, the Indian Ginseng. Cell Mol Life Sci 72(23):4445–4460CrossRefPubMedGoogle Scholar
  19. 19.
    Kuboyama T, Tohda C, Komatsu K (2005) Neuritic regeneration and synaptic reconstruction induced by withanolide a. Br J Pharmacol 144(7):961–971CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Baitharu I, Jain V, Deep SN, Hota KB, Hota SK, Prasad D, Ilavazhagan G (2013) Withania somnifera Root extract ameliorates hypobaric hypoxia induced memory impairment in rats. J Ethnopharmacol 145(2):431–441CrossRefPubMedGoogle Scholar
  21. 21.
    Baitharu I, Jain V, Deep SN, Shroff S, Sahu JK, Naik PK, Ilavazhagan G (2014) Withanolide a prevents neurodegeneration by modulating hippocampal glutathione biosynthesis during hypoxia. PLoS One 9(10):e105311. doi: 10.1371/journal.pone.0105311 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Akhoon BA, Pandey S, Tiwari S, Pandey R (2016) Withanolide a offers neuroprotection, ameliorates stress resistance and prolongs the life expectancy of Caenorhabditis elegans. Exp Gerontol 78:47–56CrossRefPubMedGoogle Scholar
  23. 23.
    Lone AM, Dar NJ, Hamid A, Shah WA, Ahmad M, Bhat BA (2015) Promise of retinoic acid-triazolyl derivatives in promoting differentiation of neuroblastoma cells. ACS Chem Neurosci 7(1):82–89CrossRefPubMedGoogle Scholar
  24. 24.
    Fairman W, Amara S (1999) Functional diversity of excitatory amino acid transporters: Ion channel and transport modes. Am J Physiol Ren Physiol 277(4):F481–F486CrossRefGoogle Scholar
  25. 25.
    Gao S-F, Bao A-M (2011) Corticotropin-releasing hormone, glutamate, and γ-aminobutyric acid in depression. Neuroscientist 17(1):124–144CrossRefPubMedGoogle Scholar
  26. 26.
    Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma P (2013) Excitotoxicity: Bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol 698(1):6–18CrossRefPubMedGoogle Scholar
  27. 27.
    Sattler R, Charlton MP, Hafner M, Tymianski M (1998) Distinct influx pathways, not calcium load, determine neuronal vulnerability to calcium neurotoxicity. J Neurochem 71(6):2349–2364CrossRefPubMedGoogle Scholar
  28. 28.
    Singh B, Saxena A, Chandan B, Gupta D, Bhutani K, Anand K (2001) Adaptogenic activity of a novel, withanolide-free aqueous fraction from the roots of Withania somnifera dun. Phytother Res 15(4):311–318CrossRefPubMedGoogle Scholar
  29. 29.
    RajaSankar S, Manivasagam T, Sankar V, Prakash S, Muthusamy R, Krishnamurti A, Surendran S (2009) Withania somnifera Root extract improves catecholamines and physiological abnormalities seen in a Parkinson’s disease model mouse. J Ethnopharmacol 125(3):369–373CrossRefPubMedGoogle Scholar
  30. 30.
    Bhattacharya S, Bhattacharya A, Sairam K, Ghosal S (2000) Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: An experimental study. Phytomedicine 7(6):463–469CrossRefPubMedGoogle Scholar
  31. 31.
    Saykally JN, Hatic H, Keeley KL, Jain SC, Ravindranath V, Citron BA (2016) Withania somnifera extract protects model neurons from in vitro traumatic injury. Cell TransplantGoogle Scholar
  32. 32.
    Yenisetti SC, Manjunath MJ (2015) Neuropharmacological properties of Withania somnifera-Indian Ginseng: An overview on experimental evidence with emphasis on clinical trials and patents. Recent Pat on CNS Drug Discov 10(2):204–215Google Scholar
  33. 33.
    Ahmad M, Saleem S, Ahmad AS, Ansari MA, Yousuf S, Hoda MN, Islam F (2005) Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced parkinsonism in rats. Hum Exp Toxicol 24(3):137–147CrossRefPubMedGoogle Scholar
  34. 34.
    Patil SP, Maki S, Khedkar SA, Rigby AC, Chan C (2010) Withanolide a and asiatic acid modulate multiple targets associated with amyloid-β precursor protein processing and amyloid-β protein clearance. J Nat Prod 73(7):1196–1202CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Baitharu I, Jain V, Deep SN, Hota KB, Hota SK, Prasad D, Ilavazhagan G (2013) Withania somnifera Root extract ameliorates hypobaric hypoxia induced memory impairment in rats. J Ethnopharmacol 145(2):431–441. doi: 10.1016/j.jep.2012.10.063 CrossRefPubMedGoogle Scholar
  36. 36.
    Soman S, Anju T, Jayanarayanan S, Antony S, Paulose C (2013) Impaired motor learning attributed to altered AMPA receptor function in the cerebellum of rats with temporal lobe epilepsy: Ameliorating effects of Withania somnifera and withanolide a. Epilepsy Behav 27(3):484–491CrossRefPubMedGoogle Scholar
  37. 37.
    Choudhary MI, Nawaz SA, Lodhi MA, Ghayur MN, Jalil S, Riaz N, Yousuf S, Malik A et al (2005) Withanolides, a new class of natural cholinesterase inhibitors with calcium antagonistic properties. Biochem Biophys Res Commun 334(1):276–287CrossRefPubMedGoogle Scholar
  38. 38.
    Grunze H, Langosch J, von Loewenich C, Walden J (2000) Modulation of neural cell membrane conductance by the herbal anxiolytic and antiepileptic drug aswal. Neuropsychobiology 42(Suppl. 1):28–32CrossRefPubMedGoogle Scholar
  39. 39.
    Gagliardi RJ (2000) Neuroprotection, excitotoxicicity and NMDA antagonists. Arq Neuropsiquiatr 58(2B):583–588CrossRefPubMedGoogle Scholar
  40. 40.
    Liu X, Ma C, Xing R, Zhang W, Tian B, Li X, Li Q, Zhang Y (2013) The calmodulin-dependent protein kinase II inhibitor KN-93 protects rat cerebral cortical neurons from N-methyl-D-aspartic acid-induced injury. Neural Regen Res 8(2):111PubMedPubMedCentralGoogle Scholar
  41. 41.
    Nicholls D (2004) Mitochondrial dysfunction and glutamate excitotoxicity studied in primary neuronal cultures. Curr Mol Med 4(2):149–177CrossRefPubMedGoogle Scholar
  42. 42.
    Reynolds IJ, Hastings TG (1995) Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J Neurosci 15(5):3318–3327PubMedGoogle Scholar
  43. 43.
    Lee H-G, Zhu X, Casadesus G, Pallàs M, Camins A, O’Neill MJ, Nakanishi S, Perry G et al (2009) The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival. Brain Res 1249:244–250CrossRefPubMedGoogle Scholar
  44. 44.
    Farooqui T, Farooqui AA (2009) Aging: An important factor for the pathogenesis of neurodegenerative diseases. Mech Ageing Dev 130(4):203–215CrossRefPubMedGoogle Scholar
  45. 45.
    Qin Z-H, Chen R-W, Wang Y, Nakai M, Chuang D-M, Chase TN (1999) Nuclear factor κB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum. J Neurosci 19(10):4023–4033PubMedGoogle Scholar
  46. 46.
    Morrison RS, Kinoshita Y (2000) The role of p53 in neuronal cell death. Cell Death Differ 7(10):868CrossRefPubMedGoogle Scholar
  47. 47.
    Li H, Zhu H, Xu C-J, Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94(4):491–501CrossRefPubMedGoogle Scholar
  48. 48.
    Luo X, Budihardjo I, Zou H, Slaughter C, Wang X (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94(4):481–490CrossRefPubMedGoogle Scholar
  49. 49.
    Zha J, Weiler S, Oh KJ, Wei MC, Korsmeyer SJ (2000) Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. Science 290(5497):1761–1765CrossRefPubMedGoogle Scholar
  50. 50.
    König H-G, Rehm M, Gudorf D, Krajewski S, Gross A, Ward MW, Prehn JH (2007) Full length bid is sufficient to induce apoptosis of cultured rat hippocampal neurons. BMC Cell Biol 8(1):7CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Ward MW, Rehm M, Duessmann H, Kacmar S, Concannon CG, Prehn JH (2006) Real time single cell analysis of bid cleavage and bid translocation during caspase-dependent and neuronal caspase-independent apoptosis. J Biol Chem 281(9):5837–5844CrossRefPubMedGoogle Scholar
  52. 52.
    Simonishvili S, Jain MR, Li H, Levison SW, Wood TL (2013) Identification of Bax-interacting proteins in oligodendrocyte progenitors during glutamate excitotoxicity and perinatal hypoxia–ischemia. ASN neuro 5(5):AN20130027CrossRefGoogle Scholar
  53. 53.
    Das A, McDowell M, Pava MJ, Smith JA, Reiter RJ, Woodward JJ, Varma AK, Ray SK et al (2010) The inhibition of apoptosis by melatonin in VSC4. 1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-α toxicity involves membrane melatonin receptors. J Pineal Res 48(2):157–169CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Culmsee C, Mattson MP (2005) p53 in neuronal apoptosis. Biochem Biophys Res Commun 331(3):761–777CrossRefPubMedGoogle Scholar
  55. 55.
    Feng Z, Jin S, Zupnick A, Hoh J, De Stanchina E, Lowe S, Prives C, Levine A (2006) p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene 25(1):1–7CrossRefPubMedGoogle Scholar
  56. 56.
    Culmsee C, Zhu X, Yu QS, Chan SL, Camandola S, Guo Z, Greig NH, Mattson MP (2001) A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid β-peptide. J Neurochem 77(1):220–228CrossRefPubMedGoogle Scholar
  57. 57.
    Duan W, Zhu X, Ladenheim B, Yu QS, Guo Z, Oyler J, Cutler RG, Cadet JL et al (2002) p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol 52(5):597–606CrossRefPubMedGoogle Scholar
  58. 58.
    Lau D, Bading H (2009) Synaptic activity-mediated suppression of p53 and induction of nuclear calcium-regulated neuroprotective genes promote survival through inhibition of mitochondrial permeability transition. J Neurosci 29(14):4420–4429CrossRefPubMedGoogle Scholar
  59. 59.
    Becattini B, Culmsee C, Leone M, Zhai D, Zhang X, Crowell KJ, Rega MF, Landshamer S et al (2006) Structure–activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting bid. Proc Natl Acad Sci 103(33):12602–12606CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Culmsee C, Zhu C, Landshamer S, Becattini B, Wagner E, Pellecchia M, Blomgren K, Plesnila N (2005) Apoptosis-inducing factor triggered by poly (ADP-ribose) polymerase and bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. J Neurosci 25(44):10262–10272CrossRefPubMedGoogle Scholar
  61. 61.
    Pinton P, Rizzuto R (2006) Bcl-2 and Ca2+ homeostasis in the endoplasmic reticulum. Cell Death & Differentiation 13(8):1409–1418CrossRefGoogle Scholar
  62. 62.
    Sánchez-Gómez MV, Alberdi E, Pérez-Navarro E, Alberch J, Matute C (2011) Bax and calpain mediate excitotoxic oligodendrocyte death induced by activation of both AMPA and kainate receptors. J Neurosci 31(8):2996–3006CrossRefPubMedGoogle Scholar
  63. 63.
    Sarafian TA, Vartavarian L, Kane DJ, Bredesen DE, Verity MA (1994) Bcl-2 expression decreases methyl mercury-induced free-radical generation and cell killing in a neural cell line. Toxicol Lett 74(2):149–155CrossRefPubMedGoogle Scholar
  64. 64.
    Lai TW, Zhang S, Wang YT (2014) Excitotoxicity and stroke: Identifying novel targets for neuroprotection. Prog Neurobiol 115:157–188CrossRefPubMedGoogle Scholar
  65. 65.
    Yang DD, Kuan C-Y, Whitmarsh AJ, Rinócn M, Zheng TS, Davis RJ, Rakic P, Flavell RA (1997) Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389(6653):865–870CrossRefPubMedGoogle Scholar
  66. 66.
    Molz S, Decker H, Dal-Cim T, Cremonez C, Cordova FM, Leal RB, Tasca CI (2008) Glutamate-induced toxicity in hippocampal slices involves apoptotic features and p38MAPK signaling. Neurochem Res 33(1):27–36CrossRefPubMedGoogle Scholar
  67. 67.
    Alessandrini A, Namura S, Moskowitz MA, Bonventre JV (1999) MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc Natl Acad Sci 96(22):12866–12869CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Skaper SD, Facci L, Strijbos PJ (2001) Neuronal protein kinase signaling cascades and excitotoxic cell death. Ann N Y Acad Sci 939(1):11–22CrossRefPubMedGoogle Scholar
  69. 69.
    Centeno C, Repici M, Chatton J, Riederer B, Bonny C, Nicod P, Price M, Clarke P et al (2007) Role of the JNK pathway in NMDA-mediated excitotoxicity of cortical neurons. Cell Death & Differentiation 14(2):240–253CrossRefGoogle Scholar
  70. 70.
    Hirt L, Badaut J, Thevenet J, Granziera C, Regli L, Maurer F, Bonny C, Bogousslavsky J (2004) D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia. Stroke 35(7):1738–1743CrossRefPubMedGoogle Scholar
  71. 71.
    Legos JJ, Erhardt JA, White RF, Lenhard SC, Chandra S, Parsons AA, Tuma RF, Barone FC (2001) SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia. Brain Res 892(1):70–77CrossRefPubMedGoogle Scholar
  72. 72.
    LePage KT, Dickey RW, Gerwick WH, Jester EL, Murray TF (2005) On the use of neuro-2a neuroblastoma cells versus intact neurons in primary culture for neurotoxicity studies. Crit Rev Neurobiol 17(1)Google Scholar
  73. 73.
    Provost P (2010) Interpretation and applicability of microRNA data to the context of Alzheimer’s and age-related diseases. Aging (Albany NY) 2(3):166–169CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Neuropharmacology LaboratoryCSIR-Indian Institute of Integrative MedicineSrinagarIndia
  2. 2.Cancer Pharmacology DivisionCSIR-Indian Institute of Integrative MedicineJammuIndia
  3. 3.Academy of Scientific and Innovative ResearchCSIR-Indian Institute of Integrative MedicineJammuIndia
  4. 4.Natural Product Chemistry DivisionIndian Institute of Integrative Medicine-CSIRJammuIndia

Personalised recommendations